Get the Stockscreener App
1.43
0.69%
-0.01
After Hours:
1.48
0.05
+3.50%
Generation Bio Co stock is traded at $1.43, with a volume of 94,480.
It is down -0.69% in the last 24 hours and down -33.18% over the past month.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$1.44
Open:
$1.46
24h Volume:
94,480
Relative Volume:
0.74
Market Cap:
$99.52M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-0.6875
EPS:
-2.08
Net Cash Flow:
$-60.14M
1W Performance:
+5.93%
1M Performance:
-33.18%
6M Performance:
-53.42%
1Y Performance:
+23.28%
1-Day Range:
$1.42
$1.54
1-Week Range:
$1.24
$1.56
52-Week Range:
$1.10
$4.65
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
1.43 | 99.52M | 0 | -126.61M | -60.14M | -2.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Generation Bio Co. Reports Q3 2024 Financials and Progress - TipRanks
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates - MSN
SK Bioscience's SKYCellflu Recognized as Next-generation World-class Product - BusinessKorea
Generation Bio's SWOT analysis: innovative gene therapy stock faces timeline hurdles - Investing.com Australia
Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections - Business Wire
Next Generation Gene pioneers gene therapy approach with China data - BioWorld Online
FY2024 EPS Estimates for Generation Bio Boosted by Analyst - MarketBeat
Earnings Update: Generation Bio Co. (NASDAQ:GBIO) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Landlord’s alleged breach doesn’t justify end of rent payments - Massachusetts Lawyers Weekly
Generation Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance UK
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028 - Chicago Star Media
Generation Bio earnings beat by $0.04, revenue topped estimates - Investing.com
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Generation Bio : Reports Recent Business Highlights and Third Quarter 2024 Financial Results Form 8 K - Marketscreener.com
Generation Bio Reports Breakthrough T-Cell Delivery, Slashes Q3 Losses by 46% | GBIO Stock News - StockTitan
Promising Penny Stocks On US Exchanges In November 2024 - Simply Wall St
Researchers Seek to Unlock the Secrets to Human Longevity - Securities.io
Bullish Generation Bio Insiders Loaded Up On US$778.9k Of Stock - Yahoo Finance
ST Launches AI-enhanced Bio-Sensing Chip for Next-gen Wearables - EE Times India
Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 13.4% in October - MarketBeat
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
Generation Bio (NASDAQ:GBIO) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT - The Bakersfield Californian
Generation Bio Announces the Presentation of Preclinical - GlobeNewswire
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress - StockTitan
Cubist Systematic Strategies LLC Has $54,000 Stake in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 6.1% in September - MarketBeat
Viral And Non-Viral Vector Manufacturing Market Report 2024-2033 | Size, Trends, Outlook - WhaTech
Alnylam’s founder brings in a $135M series A for City Therapeutics - BioWorld Online
City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine - Pulse 2.0
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine - BioSpace
Renaissance Technologies LLC Sells 28,100 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio's SWOT analysis: innovative dna tech propels stock potential - Investing.com India
Generation Bio Co. (NASDAQ:GBIO) Sees Large Increase in Short Interest - MarketBeat
Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 13.8% in September - Defense World
Rhumbline Advisers Buys 5,430 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Bank of New York Mellon Corp Has $527,000 Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Novartis, Generate:Biomedicines Sign Up-to-$1B AI Protein Drug Collaboration - Genetic Engineering & Biotechnology News
Comparative life cycle assessment for PBAT from fossil-derived and 2nd generation biobased feedstocks - ScienceDirect.com
GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy - BioSpace
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech
GrowGeneration Corp [GRWG] Investment Guide: What You Need to Know - Knox Daily
Gen Digital: Strong Growth, Good Fundamentals, And Decent Price Action Make A Buy - Seeking Alpha
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat
Insider Sale Alert: Gen Digital Inc [GEN] – Is it Time to sell? - Knox Daily
Cornercap Investment Counsel Inc. Sells 16,746 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio Co. (NASDAQ:GBIO) Shares Bought by Acadian Asset Management LLC - Defense World
Choreo LLC Takes $776,000 Position in Genmab A/S (NASDAQ:GMAB) - MarketBeat
Generation Bio Co. (NASDAQ:GBIO) Shares Sold by Los Angeles Capital Management LLC - Defense World
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Generation Bio Co Stock (GBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paone Antoinette | CHIEF OPERATING OFFICER |
Jul 01 '24 |
Sale |
2.74 |
6,719 |
18,410 |
13,807 |
| Paone Antoinette | CHIEF OPERATING OFFICER |
Jan 02 '24 |
Sale |
1.62 |
2,445 |
3,961 |
5,828 |
| Samayoa Phillip | CHIEF STRATEGY OFFICER |
Jan 02 '24 |
Sale |
1.62 |
2,445 |
3,961 |
107,256 |
| Appelhans Dannielle | Director |
Dec 08 '23 |
Buy |
1.79 |
7,363 |
13,180 |
7,363 |
| Appelhans Dannielle | Director |
Dec 08 '23 |
Buy |
1.82 |
637 |
1,159 |
12,637 |
| Appelhans Dannielle | Director |
Dec 04 '23 |
Buy |
1.50 |
12,000 |
18,000 |
12,000 |
| Quinn Anthony G. | Director |
Dec 01 '23 |
Buy |
1.41 |
88,495 |
124,778 |
88,495 |
| Rowland Charles A Jr | Director |
Dec 01 '23 |
Buy |
1.31 |
192,960 |
252,778 |
384,757 |
| Rowland Charles A Jr | Director |
Dec 04 '23 |
Buy |
1.50 |
150,000 |
225,000 |
534,757 |
| Nicholson Donald William | Director |
Dec 01 '23 |
Buy |
1.44 |
100,000 |
144,000 |
213,576 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):